Ramatercept

Drug Profile

Ramatercept

Alternative Names: ACE-031; ActRIIB-IgG1; ActRIIb:Fc Fusion Protein; HGT-4510; RAP-031

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Acceleron Pharma
  • Class Recombinant fusion proteins
  • Mechanism of Action Myostatin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Duchenne muscular dystrophy

Most Recent Events

  • 02 May 2013 Discontinued - Phase-II for Duchenne muscular dystrophy in Canada (SC)
  • 04 Aug 2011 Suspended - Phase-II for Duchenne muscular dystrophy in Canada (SC)
  • 07 Jan 2011 Acceleron Pharma receives grant from the Muscular Dystrophy Association to support clinical trials of ACE 031 in Duchenne muscular dystrophy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top